<SEC-DOCUMENT>0001193125-15-121294.txt : 20150407
<SEC-HEADER>0001193125-15-121294.hdr.sgml : 20150407
<ACCEPTANCE-DATETIME>20150407153433
ACCESSION NUMBER:		0001193125-15-121294
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150407
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150407
DATE AS OF CHANGE:		20150407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		15756235

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d905228d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;7, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36177</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1686563</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>401 Professional Drive, Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gaithersburg, MD 20879 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(240) 243-1201 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2015 GlycoMimetics, Inc. (the &#147;Company&#148;) issued a press release announcing that it has been informed by its
collaborator, Pfizer Inc., that Pfizer anticipates initiating a planned Phase 3 clinical trial with rivipansel (GMI-1070) in mid-2015. Pfizer has advised the Company that the clinical supply issue which has delayed the start of this trial has been
discussed with the FDA. Under the terms of the license agreement between the two companies, Pfizer is scheduled to make a $20 million milestone payment to the Company once the first patient is dosed in the Phase 3 clinical trial. This milestone is
the second of two scheduled milestone payments totaling $35 million upon initiation of the Phase 3 clinical trial. Pfizer previously paid the Company $15 million in May 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2. of Form 8-K, the information in this Item&nbsp;7.01, and Exhibit 99.1 hereto, shall not be deemed
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of
the Company&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific
reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April 7, 2015, &#147;GlycoMimetics Provides Update on Pfizer&#146;s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015.&#148;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>GLYCOMIMETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian M. Hahn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;7, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Brian M. Hahn</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April 7, 2015, &#147;GlycoMimetics Provides Update on Pfizer&#146;s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d905228dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g905228ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLYCOMIMETICS PROVIDES UPDATE ON PFIZER&#146;S PLANS TO INTITIATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHASE 3 TRIAL WITH RIVIPANSEL IN MID-2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; GlycoMimetics to receive $20 million milestone payment upon dosing of first patient in trial &#150; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>GAITHERSBURG, MD, APRIL&nbsp;7, 2015 </B>&#150; GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer (NYSE: PFE) has informed the
company that it anticipates initiating a planned Phase 3 clinical trial with rivipansel (GMI-1070) in mid-2015. Pfizer has advised GlycoMimetics that the clinical supply issue which has delayed the start of this trial has been discussed with the
FDA. Based on these discussions, Pfizer anticipates the study being able to start enrollment in mid-2015, following FDA review of amended study documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the license agreement between the two companies, Pfizer is scheduled to make a $20 million milestone payment to GlycoMimetics once the
first patient is dosed in the Phase 3 clinical trial. This milestone is the second of two scheduled milestone payments totaling $35 million upon initiation of the Phase 3 clinical trial. Pfizer previously paid GlycoMimetics $15 million in May 2014.
Rivipansel is initially being developed as a potential treatment for vaso-occlusive crisis (VOC) of sickle cell disease.&nbsp;Under the license agreement, Pfizer is responsible for the clinical development and regulatory submission and, if approved,
the commercialization of rivipansel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Pfizer&#146;s commitment to initiating the rivipansel Phase 3 clinical trial represents a key step in the
development of this potentially important new medication&nbsp;for treatment of pain crisis associated with sickle cell disease.&#148; said <U>Rachel King</U>, Chief Executive Officer, GlycoMimetics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rivipansel has received both Orphan Drug and Fast Track status for the treatment of VOC from the&nbsp;FDA, and Orphan Product status in the European
Union.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics&nbsp;is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical
needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical
development, regulatory approval and potential commercialization of rivipansel.&nbsp;A&nbsp;GlycoMimetics&nbsp;wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical
trials.&nbsp;Glycomimetics are molecules that mimic the structure of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carbohydrates involved in important&nbsp;biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology,&nbsp;GlycoMimetics&nbsp;is developing a
pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at&nbsp;<U>www.glycomimetics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements regarding the clinical development of rivipansel, including expected milestone payments from Pfizer.
Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the
Company&#146;s annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on March&nbsp;16, 2015, and other filings the Company makes with the SEC from time to time. Forward-looking statements speak only as of the
date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#
# # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: GlycoMimetics </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shari Annes </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: 650-888-0902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: sannes@annesassociates.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jamie Lacey-Moreira </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: 410-299-3310 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jamielacey@presscommpr.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g905228ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g905228ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@%M`P$1``(1`0,1`?_$`+H``0`"`P`#`0$`````
M```````'"`8)"@($!0,!`0$``04!`0```````````````0(#!@<(!000```&
M`@$#`P($`@4*!P$```$"`P0%!@`'"!$2"2$3%#$502(6"G$Y46$R(Q>!)+4V
M)S=WMQAX,S2T)D8H.#H1``$#`@4!!@(&!P0*`P````$`$0(A`S$2!`4&05%A
M<2(3!X&1\*&QP3(4T>%"8G(S%5*R([/Q@I)$Q!8F-A<(4R0E_]H`#`,!``(1
M`Q$`/P#OXPB81,(L6NUXI>M:G/7S8EMK5#I%6CU9:S7"XSD;6ZQ7XM`2@M(3
M4[,.6<9&,TS'`!465(3J(!UZB&$6H+2?[@?Q9[YY!3W'6H<A$H6PL'K:,JE]
MO\"\HNI-H2JAO9=1M!O-@.T04=,GH@W)]V0B222@@,:9ZF8IQAP"0>GW.X^#
M5\1VA7/2FPIYC(ANKL_UBH[1\%ND(<BA"J)F*<ARE.0Y#`8AR&`!*8I@$0,4
MP#U`0]!#)5M>6$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(N>[R(?N)^(W#R9>:7
MT.U<\S>5#E\:N1FL-0R'W"FUVU+N3QC6)NVP(EI-MUYM.4*9$T'!-Y:6^0G\
M=P1D90BF2V#5)(H*FI;PHTL2,&)"KC`RCF&#4.+FK`?$5[!4T6E/:'$/G-SZ
M1K7)_P`]?*=_PZXRNY1.4U)PDUDR>!MJYR*+071*WKC0T4WMTLWNZ\<Z.!%)
M-I;[TD115)PR:(%*8ERU8O:B[&S;B9W3(",8`R)DS-$`&5220`\C1LI"7M1I
M])"Y>F8PL0<RG*0`C$1(),GH*.X,<2.XS)L3BKXFMI:OCM([#\;^P>(^D((B
MS;5/+75$^SO/).IRCHP-G%PY,5.O,K/:GU?E5/;63!=YL1&/;%.=Z2"*3N0S
M+</;OEFW[;'<M5HY_E6<QBTIP#YO-;AF,1B22"`WG$2P6"[?[E\.W3=9[/H]
M=;.KCY09>6W<)\IC9G+R3Z#*&SDQ-N-P`RC@%"O'EZ\)50@MBZBN]>\M'BC4
MC"3%8ME,GE;46D:^34,+=[%RL,ZN%JU.T;,^IA,T5M%(9IE'O%%<P@7"S$AA
M0EV(P(QKUHQ%:TC(EB03GH],C+(994[1B_B7P))Q[JE=)7CS\Q7"/R20K5MI
M;8A:QMQ)B5S8=!;)%E6MI1*B3<JSY6'CS.UXV]0K3U$7T*X>)I)]HN2ME#>T
M%`J''ZZA_LK_`*"K9A,1S$48=XKA7L>@.!-`MIV%2F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"*C?D(\@FA?&KQ\7Y$<@CVES77=I8T"GUNEP@S=ENNP9B!LEDAJI&`LNRA
MXL[R(J4@N=Y(NFC-%-L8!4%4R22CZ?3O.`[33$JJ$)7)"$<3]7BN5&\[9\P/
MG$KL_=):R0OBE\4J"2TC:-D76P.J<K===F.5%U(2]LDUZG8]M,ED1.F8C=2L
M49?W?876<N$0,88R(,9,!7"IZ$.#VU=P!EEA(Q(5T&-II1!-X/W-^\S&HZ#Q
M)8T$\<5-8<6N$T,2$\8ND$)B^JL%HRT^2?EI45Y6YS9')E6DPGQSU(_:UJ91
MA'?8<$'ZZ56KRR!&C@"6M`PK#LKBOMCOO(VU=V)TFV2KZEP$RD"7.2!\TG<E
MSEA+$2/75?,O=CCG%LVEM'\[NX\OHVI>6&6@]6YYHQ8C\,1*8-3&(+F7HBB(
MHVJ2V3<[):ML[@GVB3*Q[AV?*)6.^RC-/H?[1'.$F<?!TBI%<B=9&OUQC#U]
MJLH<Z#)(QS"/2/&^%[!Q:T!MUK-JV\UZ;2N'M8L!`'K&`C$]05ROROGO(^87
M&W.]ET,3Y;%MXVH]YBY,Y?OS,I#"+18#.\RM88L/JT;?M,6V4V3QAV*]T9>Y
MMX>5M44UC`LNF=H2?LG2*XVYIQ:0B82ROU>I2JS<6Y@K9[294DY=-$!3'6_*
MO;'8.1F6JL#\INDJFY`#+,_OPH#U<Q,)$EY&3`+:W#O=OD/&!'1ZP_GMI#`0
MN2/J0CV6KM2!@T9B<(@$0$#*1-+N2/"#@US,MK*T6&+3\3'/0TTQD:9OK5S]
MTIPUW#>`D@/#/$;!'_I,=7;%G)YVD9)-\2L3GSS`#1:Q"G[IN;N2\,W[BU__
M`/2M$Z<DB%V#RMR#@"H9I%OPRRW&B9``1$AU1Q3G>P<OM9MGO?\`V6>5B;"]
M%O[4'.:(</.)E;((B)"8:$BT/RU^43P[VJO:1\PND[#R&X_.7R<%2.9.LSM9
MN?>L2(M!;.`M8(Q-8VB+5F`"=A.A7K>?O5<KN'G81(^)5#DUB`:TJ*^&`Q+!
M^E6S9B(V[I:W29);L;O^)9\`S$EQ(]>6FMO4'?VIM<[NU9,J6'6^UZ;7[[2)
MM:-DH=:3K-GC4)6)=KQ,RT8RL:NJT<E[T'"*2R1^I3%`0$,DABRL*2\A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A%RG?O`?Y:6D/\`OEUK_P`@^3/]8?7_`"_P'Z8-8$>']Z/<
M?L/@<%?T_P#,^7VCN/W-VQQ$D\QFB>P>8-&I]W5?6BEZEX,</MF:[I,S)2#V
MCUC9&PMB<NJY;-@M*:HZ&LN;P]@-:PK-"6<-5G[!LT%-HJ@5=R"V\/9C9=JW
M/5Z_5[A8MWM1IC9],SJ(Y_6S'*3E)\H8RB3$AXEW;GWWVW_>-IT6@T&V:B=G
M3:S\P+P@PE(6_0,!G;/&/GF"(F(F"1/,&`^-G2RY23")A$PB]*2C(V9CWD3,
M1[*5BI%LLSD(R2:(/H]^S<$%-=J\9NDU6SILNF82G(<IBF*/00$,MWK-G46I
M6=1",[,@QC("42.P@N"/%7;%^_I;T=1IISMZB!>,HDQE$C`B08@CM!=4]YJ@
MXAO!AY9-:M).;7H>K]R<3HK6E5E)J6G8K7T'/;+XG6:1K=,1FGK\U;JX3DV[
M7;1K4R3!B#@Z;=))'HF'''N1M6W[-RR_H=LMBUI&MD1!)`,X1,@,Q.))8$Y0
M[,(T7=7M;NVX;WP_1;GNUTWM=.5T2G)HDY+LX1?*`Y8`$MFF?Q$DDKHR\/\`
M_*UX`]/I_P!*6F?H/4/]3(SZ"/U_CF!@DQ!-3E'V!9U)R7D^;O#'XCIX=%:_
M?W)70/%>ANMF\B]O4+3=&;*"@6>O=A8PJ4B]`GN%BX)DLH,E8II4GJFR8(N7
M:@!^1,<E`"<`3X+4VR_<F^&M]:C5<G+-PW)[Y6J-E>Z0W\SJSAT842>T$FOK
M$B[5$JJABBX<(HM/[HQ@5%/L.:`068N3^G+]M/U*OTIL[8A_$'L^_L<.SK<!
MIO>&G>0]#C-GZ*V=1]N:]ESJ(L+?K^R1=H@SNT$T5'4<N\BG+@C*68E<$!PS
M7]MTW,8"JID-Z9*H((9\"''>.T*,*IS&T)=.5VT.%5?M$D[Y"Z=U_7]GWVJ*
MUFP-8R+IUG+7#PT@VM+B/3KLFNX+:V7<W;N%%D_<'N*'8;I+4S*<I$<W[)5H
MLA4IA$PB81,(F$3"**[ONW5FN)IE7KO<&%?F9%DA(LV3IM)+'58N7+MF@Z%5
MFQ<H))*.6*I`$YR^I!Z_AUR+:>)\BWW23UVTZ6=_2PF8RD#$-(`2(:4@20)`
MT!Q6,[SS+C/'M9#0;SJ[=C5W("<8R$R3$F407C$@`F,A4C!2IF.K)E%D?NS5
MLM>5=:QUQCW=W0>2,>K`)(2(KE?1#=VZDVORA9!'F68H,%A4*"HB44Q#Z^F9
M%?XGR+3;0-^OZ6<=H,8R%PF+99D"!;-F:1E%J5?L6,Z?F/&=5O1X[I]7;GO,
M9SB;0$GS6Q(SB^7*\1&3C-1CU7R-I<@=9:<D82)O$L\:/YU(SEJ@QC'<@*#$
MB_QC2#P6Y!!%J"P&`.G<H;L-VD'H.?3Q[A?(.4:>]J=HM1G9LEB93C%Y,^6+
MFI;P`<.0Z^7DO.^-\2U-G2[U=E"_?#@1A*;1=L\F%(N^#R+%@64QM73=ZU;/
M6BR;AH[01=-7"1NY)=NX3*JBLF8/0R:J9P,`_B`YBTX3M3-NX#&Y$D$&A!%"
M".T%9;;N0NVXW;1$K<@""*@@AP0>H(J%^^4JM,(F$3")A%&NQ]OZZU(A%.=A
M6+]/H3:SI",/]IG)7Y*K(B"CHG;"1DD='VB."#U4`@&Z^G7H/3WMBXQOG)9W
M+>R6/7G9`,_/;@PDX'\R<7=C@_>L=Y#RSC_%;=J[OVH]"%XR$#DN3<Q8G^7"
M;,XQ;N7Q-D;[UIJJ&K,Y;)=TDSN!3+5XC",>/';]HFW:.EWOQ@33.@V;(OT!
M4]SM.`K%`"B/4`^O8>&[_P`CU6HTFVVHF[I:7,TXQ$220(N]23&3,X\I+LOB
MY#SGCO&-'IM;NMV0LZNMH1A*4I1`C(R9@0`)1=V/F`9U*$%.15EAHNPP3U*1
MAII@UDXQ\B!RINF+U$B[=8"*D362$Z9PZD.4IR#U*8`,`@&/ZS2:G0:JYHM9
M`V]5:F83B<1*)8BC@UZ@D'$$A9+HM9I=QTEK7Z*8N:2]",X2&$HR#@U8BG0@
M$8$`KZN?,OJ3")A$PB811IN+<.MN/^L+IN;<%I:4C66NX96PW.V/FDF^:04,
M@JB@J^79PS*2E'!"JKD+VH(*G$3>A<(OLZYV#3MM:]HFU==SB%GU_LVFUC8-
M%LC5!ZU;6&G7.$8V.L3C=K)-F4BV0EH220<$37126(50`.0I@$H,*'%2006.
M*S+"A,(F$3")A$PBY3OW@/\`+2TA_P!\NM?^0?)G^L/K_E_@/TP:P(\/[T>X
M_8?`X*_I_P"9\OM'<?N;MCB)3Y*__N)YZ#_+AX$^OX?[WN>OH']89T+[%?BW
M8=^F_P"([_N'B>G,W_L.?+LX<8ZNG7_=?J/3P*QS.@5S2F$3")A$PBIGSK_D
MS^9[Z?[\.&GUZ]/];N'7]'J/\/QSD3W;_P"]]1_!9_RH=.OAC+`8KM_V6?\`
MY"T#.^>_@W_SW>WZST&%5T.>)J:BZWXG.#%BG7J4;"P/#_5,U,2+GK[+"+BZ
M$R?2#U?VBG-[35H@<YNT!'H4>@#FLQ^`/_9'V!;)`=A%NYG^IZ^#U6C'QR\4
MX_SD[RV;Y8.?D;([$T-&;,M6N.$7%.UJNE=8UJA4V19)'M%G@4WQXRR)'=H$
M:/V!R?`F)UM(KOTEVY6B"<]Y#=WSQ[V)B1@"#3!K\I9`(1Q#UI]SM(5#@N1W
M,W4-*\5^,4Y1/\+IGCGHF5UI\(8TNO7^I*"[I)(\2JE^$G5EH`\(DV`%S]"%
M0`H=P]`]1P?,!$U`##N`##Y"GA167)=SCCWN7+]KFJH-Q.\./';@[R\OO)KB
MU==JZCH.R*0%>M/%2"L?S-%R-H,\<+C<5F,Z27FRA')J`>,8I.$@BG*CCXZY
M62XL"!1^TG[W=L'[^R@54IRD/-7Z#]#5>C`,U:&Z;D;+#_N._*/+4RNL[A<(
MOQZZJD:I4I&=-5H^T65E!Z-<P5=?V8D183UUG-RB2395^#!\+0BHJ@W6[/;-
M4?Y8\3]@5<G]`-BY^];8_&ESZK'D<XR,=]Q-&>ZFN$/>+KJW;FFI:=/99O4^
MRJ/*`C(5.6FU*]5#R"[FOOXV43.:.:'(C(D343*JFH4((;P_61\,,,1UJK<H
MY2V(^GRK0@]0L:W+Y"3T+R(<9_'=K74'^+5]W)K^W;BW!<?UZM5(OCOJ&NJ.
MFL1;YF*;42W?JU[;I6'?,6;`[R&['GPB*+@1\FHG`J_</OI\Z_+O01)B9=`W
MQ\/#K\.VD%<S/+NGICD&7A3P[XU7WGCS11@T+%;=6:\GXZH4C3T+(MVRT9);
M?V=)Q\O$U1==.29N/B*I))D;NT!<NV9G+;W9&.!9P_<[=?`NV/7"JF,"1F-(
M]_7M;M85;JQ`<@@5JN'F!Y_\/DF5\\D7BCM>H^.;R38-I[?''C>5(Y`M-6(2
M\DBT9*;!IE9([<MXUE]P10<22TC&HK.D^QFBY5<(H%I,@(YI4H7[J.!\:A^U
ML,P"K%N$RT"WCT#.2>P!CVMVK;AO7G?Q@X[\2U^;>P-CLS\?%J?6;I6+1`-U
M920OS*\-V3BCQ5'A%/AOIFP6[[BB5JU,"(I`8ZKHS=!%PJE-,7#4KTK05[*X
MX?!6Q$DD#H"3X`.?IUZ+3G7?+1Y==MUQOO71G@^NDYQK<(.9J$<7SDI1*-N>
M[U`%&SF,L$'K:8AV5L;+R\-W+MVK*%GDW(KI_&<."$[ECTH"_>6JY!<,]`'[
M:@-V5F$8TE+SU=@:$#PJYHX^1!=;0?'5Y)=&>2#5L]<M9L[#0=DZVF_T=O;0
M6PFZ<9L_3%X35?-5(:S1G1-1Q$OW<2[+'2)4TBNOBK)*I-GK9VS;G!J,'^]N
M\=,02.^A5$XY9-B.A[0<#\53WFO.GG^0MI:I]ZJ5;BX""0$I3=>QO#(3+W\H
MD*8"(/)1<!'U#H43`/;TSKSVGT<=%PG3W2PEJ+ERX?$S-N/Q,81^H8KBGWDU
MTM?SW4VHN8Z:U:M#P%L7)=,!*<G\"79;*M3[J8N>,,?M&6737<5"GOFLZF=;
MHJYFZHW4CDVZJBA@_P`^GU&[=0@=?S&=E`/KFA.2\4O6_<"YQ[2@B&JU43;+
M.!"\1)V'[-MY`]@@7P71?%>86+OMO;Y+JR)3TFDD+H=C*Y8!BSG]JZ8Q([3,
M-BRU*:.MD@QY`:[MLHX5.\E[\Q/)OU2=3.`M$FK%2SPWH`&*?[DL)Q+UZ"`]
M`ZATSI7E^V:>[PG7;9IX@6;.BEDB.GHQ$X1`[LD6'@N5^%;KJ;//=OW74R)O
MWM?'/,_M>O,V[DB>_/)SXJ]?.M_KB*L6MW5SH<Q:WR\?,>R[AKP6I",?'O&9
MQBI!%2L63Y355=^8Y5$A:K$$3`!Q`?RZ?]G[.^ZG1:^UM6LM::U&=MQ/3F]Y
MI1D,\3ZMII`18@YP:$@==V>]M[CVEUVW7MXT-W57I0N-*WJ18\L)1.28]&\\
M29N",DA4"1Z35OODNTXYRE.JZ-!&P1DK#"J@X1L0PQ8MI'.$X\K1%L:"EOF"
MBW`I@ZJIC]`'Z]<Q3AO`;O.=/JMPEK/1U%NZQ!M9\\I`R<GU(97/<>WN68<Y
M]QK7M_JM)ML=#Z^FNV7!%WT\D8$0RB/I3S,&/XAV=Z@.6\ASAM*-W##4KH:F
MX753:/Y2>59R4H@W53!PX:E2AEHY%5)-4H&1*JX`IA#JH'7H&9:;V1C<TQA>
MW.`W.(!E&%O-"!(H"\Q(@L6D1'^&BP?5^_DK6JC.QM4SM,B1&<[IC.8!K(`6
MY0!#AXB4ZMY@ZR.[\_H9`Y4]8425MJ#>/:R,Q+3)UXEK%@ND515H=DR;2"IC
M-#J`FJN=9)$%BF`GND[5!^':/9C5W`9<AUEO2SE<E&$(-,S8L)"4C$>8#-&(
M!EE(,LI>(]#>O?31VR(\:T5W5VXVXSN7+CPC!PYB8QC(^5\LI&0CF!$<P:1L
M-QWY%0>_8:67;Q*M<L5=5:DFH)5X602!N^!?X,C'O@;LS.FK@S50IRF2(=!0
MO:;J!B'/A'-^#ZSAFJM0N71?T5\')<$<M8MFC*+RRD."/,1(%Q4$#/>`\_T/
M.M)=N6K1T^OTY`N6C+/23Y91GECF!RD'R@Q(8T,28AVMS8BZM;G="UM37NQK
M#'/%HY^X0771C@D&WN%=L8M!BS?R$NLS7()%3%*DF!BF[#'#\V9/QWVGU.X[
M9#>=]U<-!H9Q$H@@&64_AE(RE&,!(5#F18AP"L4Y/[QZ7;-UGL?'M'/<=PMS
M,)$$B`F/Q1@(QG.X8FA81#@L2R\=5<VXFT6YO1-ETYWKB>>NT8]DZ7=++1P2
M+@I/C,9=N_91[^%5=*'*5(Y@53$3E[Q3+^;)Y%[3:G;MLEO.PZJ&OT4(F4@(
M@2RC&4#&4HW`&)(&4L"PD:*.,>\NDW/=8['R+23V[7SD(QD9$PSG",Q*,)6S
M)P(DY@Y#F(JJU\]]EKV"[--;'K:T>AK]V#I&Q'?G62G_`-35ROR9R),!C6Y&
M7VXZ@I"(.7'N"41Z$_LAGOLUL$-%M,M^%\3GK8L;65C;]*[<@YEF.;,S_ABS
M]<5KKWRY'<U^\1X[+3FW#03S"[F)%WUK5J;".09<CY?QR=GI@OUVAMFF;)T3
MK>PWS4\X*E7MKZB1'VN^C"O2MXVH522>/Q=NZ3)-5&-B*LB!FXM142^(!DW'
MYC!E''N-;KL/,-=H=FW*SEU&ECJ)Y]/ZD7E>O1C'*+\2)6FEYL['.1*%`57R
M7E.T<AX3MVOWS:K^;3:N6FMY-3Z<FA8LSE+-+3S!C=>+QR.,@,;E2%?QQM+7
M>F](4NUR:`0%=&IUE*N5EBX^YR"YW<*U<LH2-66*U/*.$4!$5'*@)@8I#+*"
M7J.:8AQW?.4<LU>VZ8^OK_S-TW;LADB,LR)7)@.(`G"(=B1&(-%O6YR;C_$N
M':/=-5'\OMWY:R+5F!SS.:V#&W`G*9D#&<F<`RD154[=>1&9.[4>1>H"*UU!
M0Y#J.K(Z^6<A%&_YE'C>!48L5!24]2"18"&4)^8P!^?:%OV/TT;8M:G=&ULA
M0"T&%#T-S-*HQ>+@&@Z:DN^_VKE=-[2[2^@B2"97I9C48R%HQB6-0TF)%3UN
M!J+DC0=M4VP6UL9S734YHJ^N$7*A[RT*R1:.'II%-=H0Y9&-.W9K"4Z9`5ZI
M&`R91$H&UCR;@N\<:W6QMES+?_-2$;$X4%R1D(Y6E^&0,HN"6J&D:MMGBGN#
ML?*MGO[M:S:?\I$ROPG4VXB)EF>+B4"(R((#^4@Q!9ZE2'D.<A,O'$+JM5[2
MV3_XHR+N;7;2BS95809N%_8BG,;&.W3=%0Q6QCK?F]`5$"B([)L^R$?RL8:K
M<HPW6<'RBV#`$#S`/,2F`2!G`CVY:LM67_?V8U<[FCVN4]GA/+GE<(F03Y9%
MK<H0)`)R$R<TST=;$*3:FMXJ5>M[%E)1S2PQ;6408R[-9A(-DW)`,":[=<A#
M"7KZIJEZI+IB51,QDSE,.D=UVZ[M.Y7]LO2A.[8N2@90D)1+'$$$_$'S1+QD
M!($#?FS[G:WG:]/NMB%RW:U%J,Q&<3&0S!V(('P(\L@THDQ()RC//7I+53YP
M_P"4OSM_X&RO^FH3'[,OX9?85(PE_#+^Z5462\B33QD>$7QE\AI#5:>W&$[H
M'@?J5[`+7[_#A*&:7+CG#2#FV*SOZ*O7R4X-&MF$S/X:7O`KU]]/LZ&``8T`
M!^H/V#[!X=%=,,]Z0[SW]?IVK\">6/R(<A(B1W+P`\4%KW3Q4CA7?U?:VZ]U
MU30]TWK7V"+DSR:U+JJPM#64(.2`J:T3('+(?<D2BF1L#HWQTSAG8X/XT+=O
M8/@:@%4B$<)2&8@885[\#V&H%7$B%LA\<_D"UGY&]`*;GH=9L^N;+5;E.ZOW
M!J"\)^S<]3[2JZ;):>J,R(MF0OD2-I)!=J[!!N*R2O8JBW=).6R#Z?3L\#7M
M`-%3..4L[T!^=:C$'N/V*BNWO,EL6\[YV+QA\87"F\<_-D:;F%:YN?9OZ^KF
MF..>M;(T<J-7]9':%L;.(JV69@[:+MU6A5HQ-4Z2AV:[T$%BEG`M+MK\G_1W
M5QQ:H0%,Y`'S[>S`X8M0XO18?&>9KD5QKV5K[7OE:\?=JX;4[9D_'4VK<G*!
MM.N[WT*%ME%&S5BTN;ZK,3&U]'/5Q55`[B1>O$$/SJM2H)+N20XZT=@*O6M/
MT8D@O0"3281()M$D#HU6^]WB`U22S.%T(85I,(N4[]X#_+2TA_WRZU_Y!\F?
MZP^O^7^`_3!K`CP_O1[C]A\#@K^G_F?+[1W'[F[8XB4^2O\`^XGGH/\`+AX$
M^OX?[WN>OH']89T+[%?BW8=^F_XCO^X>)Z<S?^PY\NSAQCJZ=?\`=?J/3P*Q
MS.@5S2F$3")A$PBIGSK_`)-'F>_XX<-?Q[?_`)=PZ_'\`SD3W;_[WU'\%G_*
MAUZ=YQ&(J%V][+_]@Z#^._T?_>+O3[.@Q-%OU\:%.-L3PT\1M?D=E8&O7!BC
MTXCXQ1[61K-JTD(5V)`*H;M;"][^G:8>A?H.:T@6$3V"/V!;+S$2S#\6-2_S
M(Q\1BJ$_MF][1K7AS:?'SL%)&D\G.!>V=OT+9&KI95)O92P%GVG:KHG;6K4Z
MQCR4.TN=JDX9==$#%059H&4[2.VIUXBV2+=GC@\3\'!;PZ8"Y=AE.:/X"`W;
M4`U%`"QP%`,*+<[S+TIR'WUJ)M1^,G+&3X:;'1N,-.K[<B=3US<KIS6F#&8;
M2=/-4;18*U&IHS+M^V7,\!R*J(LP*4@@H82U.SMBRMQ,1^(./IXKFKV3.>47
MB?Y/_'!PX5\MMKYC3F_MI1E\W?J@G&34FI_T?QUH-@BK#;GMD?0\W?YA1IL&
MF5VT-VQD0CU$"1"ZGO`)DS8\Q?`?`=[_`*!W="09"ZT96S)LM`V.(-?F"*$]
MXZJXW&C_`/IK\CG_`&-:-_\`3Z#R3^`>)^Y)?R(^/Z5A<=::[XC_`#5[9BKE
M)L:+PJ\J6NK/OF+GGY`8U/77*?2<;(S^TT?=*54&_P"JXAZ\DGOM)E4?/[+&
M(%[_`(A2Y`&:1`Q9^G3'PQ?JY)PJZMR#`EX].[!QX``$8"AZEY)\&%/L7)6\
M\R/,-M.&=,+7S?V;)TKC_'RI2F?TWB?J&13J=2C&W^;-C-#V&5K*"#XI2^V\
M/7&[P/5<PC#N`>T#L^SH6;,Y+D=@"IN&+"`Z#&G6O0GPQ:E`OE_MW!J<HQ\G
M]IL*A77*>4\D^]V'(!S-'3&\MXB,=(!KN+E$#`5VTJ[*8<68(],Y>PC_`.XI
MICV)`1-T?]ERWS9_BWAT#!@INL2\?P'"C=W?T`=Z]K8#HJFXB%GX:5A+)&1<
MU7Y>/>1TW$3;)I(PTG%/$%$'["5CWZ:S)['NFIS$626(9,Z8B!@$!''>K8)!
M<8KG)\\S*HS'(OPIT[<945.-4[SU9)[.BIA!D:AR%F:MJBSUFPN17Y`C@A71
MI.6;."+F*V-%KO05`4P'I!#Q_=H&9P7.!%1\QX,2"+UFCR`J`X[78LU1@6/4
M4=J!NDK)5A<W&HV-<K_[GGDHQTJ"9(>S>.:KV7E0QB$6S>&:;D+L2C-ZH\F"
M(.#-QM3R@*0+@AA*F\53?NE!3,0RRXJ/3H#\R1UPP`H:X&KTN$GTA%RV8^'U
M85+U#EZ%G!N!IBJMMZ<D=ZN9(ICQ,E#;0]ISW=Y6@6&2_3<*4BQ4_59K&R!C
MI&``Z_'Z_P!0]/<LW&[Q#@>SV],WYJW=TCC#-Z4/5FX[#.($A^\N2>';9:YK
M[B;W=U+_`)2Y9UC&AR^K/T;=>V,)$Q/;!5L#8EFINM-@Z)=IK()R5ZC7TF4%
MP]IFM7A>-)V.,F!1%0SV4C8TX&`P%*#(P"`]X"&>_P!$V_=M^T/,;)C+)HY1
MA3\0NY96YO\`NPG='^N.Q:Z_K^Y;/QS7\'O"4?4UT)3K2)M9HW8$?O3A9/=Z
M9?%31R'U<XU'0>-LB@B#>83KTF,T<3@8Z%A^XL+:"2@E]M0_QW,ZNB42CT`C
M<`ZAZ";$^#<AAR;>=^LS.;22OP]/L-K+*RXZ!XVX2/?(K,O<#C4^*;%QV_".
M761L3]3NNYX7V/4M*Y.([!`8*2/(#*(SA])S;<O:WF*K-RB`!VG*",@->=IE
M!<`+[O:FL'X`'XA]<\+V5T\M(=WTD_YEJ_;@:U>/JQ_#TJ,>N!_"%D'OOJ8Z
MV.RZVV/\.]I[LQ082]&0\W6APP&(_$5[GD':D=[$U8V4[TR.X)VU.MW`4@$5
MG$TS=HBF8"G2!3J(CW!T$/3^FCV3N&ULFXW`Q,;T2WA;)^ME<]^;0O<@VNU)
MQ&=F42?&X!V='[^E%9'FE`0L?QK?Q[&+9M6-<E:@$$U0:IE0B`1D48I+X10`
M`:=D<\50`Q?42*&+]##F!>U.MU5WGMN]=N2E=U$+_J$R+S>$KA?^T3.(DQZC
M-T6Q?>'0:2U[=7;-JU&-G37-/Z0$0UMIQMC+_9`A(Q!'0Y>J_G!R"AT^/K);
M[>S44LDU9CS@J-TU?N0)/EHE-!Z"A!!P@5@V*0$S=Q.TP^GYC9/NYK-5+FTX
M&<Q'3VK0MU;*\1,F+&AS$EZ%QV`*GV7T.DCP*W,0@9:F]>-QP^9IFV!)Q49(
M@-4,>\A55X1INHRT;V2AO<^;'T>03B1ZE%7Y321<E8_F'L**GNID]?0.O]&;
M%]W)6M1MNSRU;>C/51,^@RF(S>`8E:Q]F(W=-NN]PT3F_;T<A;ZG-&9R]Q+@
M*&>,L3O21EK2ZT7,5V,G6S-@6:-+)U1:54CG"SGVSQY;+%2C@K,'!.CDS;L*
M)S)`J(B*>95[@:CA]C3Z:',+-^YI#*7IY#>$!(`/F]*<!F;\&9RV?*WF6(>V
M^FYO?U.JN<)O:>UK!"'J9Q8,S`F39?6A,Y7_`!Y&#Y,SG*IEV-QZY<[8E(E7
M8#ZFSDS$,G18Q0CVF0TH2.4<(&6!0\%$1;MZR0=B44_>%1-NHJ?V^P53]^+;
M%SCVSXW8NPV6&JLZ6Y(9QEOSCF8M2Y.8C(AWRL9"(=Q$-EW(.`^ZW*-1:GOL
M])>U=J$LAS:>W/*X>MNW`RB"S9G$3(LQF7S3GNE+(Z^T6C/G*I.I)RB4T<J@
M*E/+)PE=+)'*J`B"I3/`.(&ZCW?7/+]FI::>];Q+1!M&3`VZ-Y/4NY:=/*U%
M['OE'50V'98:XOK0)BY5_.+=K/7KYGJO[S<#_8GH4W:8>B;,.\/[!>ZI,![3
M!VC^8_;U#U#T*/H/X1[2'_JS>!_%_G23WF'_`$;L98X1_P`B/T^:C7E\N[&J
M<86CPSE.OCK&.7`S7J+0[L8VM)21FA#`"2CELR]CIU$>TJA?H!AZ^][8PM#<
MN0W;64ZW\_(5QRY[IB_8#+-XD'%@V/>[-RZ=KXW9O9AM_P#3HFF!EDLB>7M(
MCE9\`1@Y?:_38BG,J;"1=.:1)J8I#-B1*4>FW5C'T4X:D`BQNPHIO?G(&[E3
MG[C+&,(G$1$<YNW/4[G=W2]J-SE<_JHNG.9$B8G$L1^Z8D,`&$6`#`!=1;5I
M=JL[39TVTPM?T<V1Z8B`82MR#@_O"0+DES)R2Y)7SXRHZ]D:'(5>K,(!&BV>
M+F&"J53"/3BGK.:;KQ\FLU7C0.T5563.<@J!W"`EZ#_9Z9]%_<=ZT^\0U^X3
MOG=]/<A(&\9&<90(E`$3\P`+%BWUKY[&U[%J=EN;=MMO3C9=3;N1(L"`MRC<
M!A,Q,/*20X)KAW+59,4W=/%9M,SM4?P&R-'RTD"<N*S>/L52E4P?%BT6]JA3
MF54BGXO$RM3N&JGMBN0B0K=P@EG16EW7BGN-<M:+<H7]!RZU;>#&5N]'RYR;
M-P4G%B9B,QFRO(08&2YCU>S\P]L+5[7[7<T^X\+NW/\`$<1NV9C-D`OVS6$L
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MHHIE`"D3(`!Z!D8U7S+F6X,EN-+WK^YH::=^YHW2,VU+WC7+"*,/S$]K6G4>
MX;,W?Q*:9D>V6E+B+<Y3`)3&4*3J;T`<-Y\H[F^(!^TGYJ[(YLL#^$%NS$1)
M/C7$-T5KOVWT9J)GXC>-\IJLD>I)V1[LJ9W#))E3^_RNX@V'8XVTN;:K[R[M
MQ*H1T>P09J+F[SPJ3$Q`!(R89`[`7`P-,,0[`58N>M:U4WW]2K@-2A%.X$GJ
MX^X8#=Y-Q$!,M6[:QQD/*LF\I$R+5";9,GS5":CY)L[@GS=)^FJBE*,9=-%1
MHJ4`52<E(9,0.!1RH/T5G#Z?!?8R$3"+E._>`_RT](!^(\Y=:@`?T_[`N3/I
M]?7T_C_`?ID2;(0>[ZB">AZ`DT-!@5>L,)N<`WVBN!^=&[8XB1N6#I:(VK1N
M8C%BO<N)^Q^#O%W6C;D/KMS&[!UC4K;J/8/)RR6$+_*U%_+O:C4WD7N*-^-9
M'+8*XFX;N6[M^V7*BFON+VGY7L_&]7K--O$Y6HZKTLLV)A'T_5<3:L7SAI`$
M8YC$`%:2]YN&[[RG1:/4;+;C>N:(WC.V[7)"[Z-8`@"67TB\<V8N,L956/,)
M!A*L6DG%O6DE&R#=%XPD&#E%XQ>M'!"JMW31VW.H@Y;KI&`Q#D,8IBB`@(AG
M45J[:OVQ=LRC.U(.)1((([010CP7(=^Q>TUV6GU,)6[\"THR!C*)&((+$'N(
M7MY6K281,(L4N5YJ&OH?[[<[!'5^,.[;1S55\J/R)*5?*`C'PT-'HE5D)N<D
MUQ!-JQ9I+NW2H@1),YQ`!^#<MUV[9]*=;N=Z%C3`MFD6<]@&,B>D8@D]B]3:
M-EW;?]8-OV;3W=1JY?LP#L'`S2/X8Q<@&4B(AZE5F\BL;.ZW\(WD=G-OP3S2
M\CREW#QHF=#4+:CR$JFT+]"T78'&5E,OFNO'4JI9HI[\&DR4I]L>H-YAI%(?
M)>-&OYB%XZYYOFCY)R2_NVW"?Y,Y`#(,?)",<S.0',28YC@QD!4#N;VYV#7<
M8XQI-EW')+6VC<,O3E*41ZEV<VS903E$@),,I+B,I1(D>B?P_P#\K7@#]0_^
MJ6F?0>HB'_LR,^HCZB/\<PP4B!CY1]@67R#%@01VAF/@U/E15MY]>&>J\G]U
M07,?B_O6Z<'.<E79IM$]YZNCB/8?8K1F@DBRC-L5!O)0/ZD,+1LFP.]!UU7C
MNC=^VDFZ#9NE+.0_T_T##O`=Q$!50GE!B0\#T^_M=J.%7D>/'[FM<BM15Y\^
M/UO`*M#1P;8:ZAFC;33!0X$&<2I)]')ZX),IHF,8J?NBT$Y0#L#J)@@.&!;O
M/5NT#!SWN`W>PJ>UERD/A6K]^!ZX`##',<%;_P`<WB5IG".\;'Y([6W%=^7'
M-O=34&6S^2^STA0DDH=0S%9Q4-?0"LC-*56L**QC0ARJ/72RB#)L@F+=HBDT
M3GZSV_3##[!@(@1*X\<D0T'?O)[3^H`=@6::JX"6[7OE<Y0>0YYL"N2--WYQ
M^U]IN(UVVBY-*S0$G34]=INIF2E53C%.6#S]$*"FFD`*![Y>O]D>LO1NGZ?]
M"@S>V(=A/ZOO^0[::SOW*](J7*"G<$.!5=A&TYR9Y,<L8,^IY),1,[UM0JW"
M2$3M[8,PFV'Y:M5CX:U-E'353M0<)-%71>]6.*4*2"1E`-?DSAWJ#@6I5B5-
MN0BY>K?0_6U"#6A%9#HDTEI^C<?=/ZQT;K.*3A:!J6BUG7U2CB%)[B4)5HEK
M$,UGBI"$^7)O2-??=N#`*CETHHJH)CG,(U$DU))/>J)'-(R[2M1/*[Q-[5<<
MG)SG7XV.3@\,>4EYCF\9NN!F:HE>=!\A460#\1_L"EKBX;Q-F]"^])(L7XJ&
M)[Z2"#Y1=XM2U7^G1^_``,[,"`Q)DK@N4$)AXO7O;#X]'QRDBK1:$-D^-SR]
M<WX\NHN>/D+TY1>+TM\!#9FL^%FKYFMVS;T$@#<LC6)V]7AC'R5=CID4!,Y*
M09&-6]TY%8Y1/VR$59G:F([:5[NIH1T!<.\&4&>`\WWN[BIP9@"^-79CM/Y0
M^//CMRTX=DX3;.C+"?5L/6:E!T2?0G7$KL37LQK^*2B*1=Z[;K26??.+A!-$
MA3.[??*%\@NNBY!5)PL4TEI$D]7^O'%\0X[P2"X)"@3D)9P:N#XL0?M"U6P?
M"+]P/JRLCIC67E(X[W+5T4W"O5#:^X=%K27(&!JR9/A,C.C'K5KAK+8(Q@0I
MB.IB3DG"ZXC[C@2@3M585>0`<]I^+X_-ZU%%4#9RY2#UKU'9W.!C2I-&6P+Q
MX^,^D\`*'M%XVV+:M[\G]_3#FX;_`.4.RO>&[;-MP_<5(HHMCR$RX@:K!NI1
M=5!G\QXX,NX656<*F,F5*[9E;C>C*\#*R)#,.V(-0.RCM7K4DDD_/J3>NV91
MLY87C`B):@DU#@Y&:M7ZJ>^+O&J3T&O<WDW/15@>V5*#;,U8QN\;@Q:QAY15
MVFH#H0!07BKQ$?0/R^S]?4<V/[A<]L<SAI;6DLW+%K3FX9"1B<QGD`(;#*(G
M_:6K/;3VZU'!IZR]K+]J_>U(MB)@)#*(9S('-CF,H_[*P:Y<+RVK?([/^^1"
M=1?66&LDU5EF;GYCU5I\-:8:`LD7XPH3+QL<Z@CT-T7.'7KT-GK[5[J2VWAO
M_+WHW3N<+%RU;O"0:(EF$"V+VXD`?PA>-O'M!'=.<?\`,OK6AM4]1;NW+)C+
M-(QRFX'P:Y*))Z^8X44R<FM%OM\4^#@(J98P4E"V-.83>2+==PV49FC9!DZ:
M=C;^](JHJY1.!O4O1,0$/4!#%N`<OM<.W2[K=1:G>L7;!@8Q(!S9XR$J]`!(
M-W]RRWW'X5>YOM%G0::[;L:FSJ!<$I@D9<DXRC2KDRB7_=;JH6VSQ&N&RJCI
MVO$N%?9/=9T\:L^?.6DBJG*>TE%M6BS8J*9!322;1@=>\O>)C>HF^N95QKW+
MVW8-TW37'2WIV-PU(NQB)1&1S,R!?$DSZ%J4`6(<J]JMUY%M&T;?'5V(7]MT
MALRD8S(FPMQB0V``AU#UJ2LWY'<:IS=MNI5CBK%$0R%79F:NFTFW>.#O.LFF
M_#V?C)B0@=A1*/<(]1$/0.GKY7!>>Z3B6VZO0ZBQ=NSU$G!B8C+Y#&KX]M%[
M'N#[=ZWF6ZZ/<=+J+5F&FBTA,2.;SB5&P[*J6M_ZPD-PZREZ)%R3&)>23V'=
M)OY!-PLW0+&R3=\H`IMO[PQU2("0/J`=W7,9X9R"UQCD%K>+]N=VU;C,&,2`
M3G@8BI'0D'IACT.5<YXW>Y9QN]L>GN0M7KLK9$I`D#).,C2-:@$=<<.H:`U?
M(:>UE$424DF4N\C7LPZ._CTW"+98LE(N'R8`FY_O"G2(L!1_`>F.9\@M<GY!
M=WBQ;G:M7(P`C(@D9(")J!U()ZXX]`X-QN]Q/C=G8]1<A=O6Y7"91!`.><I"
MDJT!`Z88=3$W'+C7.Z4M]VLLO8XF:2M+0&S9O'(/$%&@_<U'YA7%R0"J`)3`
M4!*(=!`?0>OIDO.>>:3EFV:30::Q<M2TTG)D8D2\@C1L%BOM][=ZWAV[:W<=
M5J+5Z.JBP$!(&/G,JOCV44>;,X3/G5S>7[2MZ/KR6D7CA^O&>Y*1K9@]>'%9
MVM!S,&I\^,:KKF$P-01,FEW=$S$3`J9?;X_[L6[6UQV7EFC&NTL(B(FT)2E&
M-(BY;N#+,@4SY@2PS"4B9'PN2>SEV]N\]]X=K3M^KN3,C!YQC&4JR-NY;.>`
M)KZ>4Q!)RF,1&`\-9<,+5'7YAL3;&TY.SS,.]:OF(0TI.JR,@NS5!1M]UL\L
MHE*D9D`G:=NB0#*%,(`L4`$#5;_[J;;>V6>Q\:VZWI])=C*,L\+8C$2QR6H`
MPS%W$I&AKE)PIXY[0[I8WVWR#E.Z7=5K+,HRCDG=,Y&)\N>],B>4,QC$5!;,
M`&,O<H>/TWON/I[*&GXN!-6GLPZ<'DV[MP5R6208))D1!J`B44Q:")N[^D.F
M8S[>\UTG#+^JNZJQ<O"_"`&0@-E,B7?MS+*O<K@FLYSI])9T=^U8.GG<D3,2
M+YQ$!LO9E7H[^XY36X*)KNI15ABX9S2@1*X=R"+MP@[*G#-HP01(V2!3N%1#
MN`3=OI^'4?2[POG.EXOO&NW/46+EVWJW:,2`0\S.KEL"W7Q5GG7M]K.6;)M^
MU:746[-S1L\I"1$FMB%&#XA^G@L]NN@ZQL?4M=UI;!`'=;@89C$6*-3`KJ'F
M(F);QOW!@14"@JR<@B)5FRG0BR(]/R*%343\?:>9[AL7);^_[;_+OWIRG:EA
M.$YF66382#O&0K&7;$RB?<WC@VV\AXMI^.[K_-T]BW&%V`\UNY"`AFB^,2S2
M@:2CV2$91I0/!C=;!NM`0^YH\E65%1$S$9"V1K=9JX$H.@6@FH.X[JJ0Q^Y/
MW3%/T`!-^81#:X]WN*7IC6ZO:I_U(,<V6S,B0P:X<LJ48Y01V4KIT^RO,;%N
M6@T>\0_I9<9<U^`,3B]J.:%0[C,0>VM+:ZGXSQ&K]9VR@HV^RNWMW:K(SEBC
MW:T2HQ559+,DUJW'?(>M8A5`BYA,K_>+.!`H*F,0B9$]9\DY[K.0[]I]ZGIM
M/"WI)`V[4HB8($A(B[)HRN`D,WEC$?@$9&4I;5XM[=:+C7'=5L4-5J9W=9&0
MNW8R-LQ)B8@V8/*-LQ!=_-*1;.91$8QJ6;@5M1%%S566XV!:"[D".W$>;]1H
M(N3H'`6[]S5$EU(5>02#U+W.1$I@]#_B&S/_`#)QV4H[C<VN9WJ-L@2_PB0^
M,1>(]01/5H?ZJU5_X.Y-",MKM;O`;%*X)&'^*`6-)&P)>F9CH\\?VNJF7>L,
MXTKQOKVE];-)F3DK?),J"T?-D%1=.3S[]1[/.':S<HHH*V-TY,S(B)O_``W@
MD)U!/TQ3A^KM\JYY?Y3OTK5NQIK<M3*)(8>E$1M@`U(M1`F9-C`$L9!\PYMH
M[O#_`&[T_$./1O7;^JN1TL9`%SZLC*Z9$4!NR)@(DX7"(N(EK4ZJJ4M1M>52
MK3T[(V6;BHI%*5F)-ZN_7</E!,NX01<.#&5&/8&4^.V`?4&Z1.O4W41UWR+<
MM-N^]ZG<='9AI]+=N$PMQ`B!$4!(%,TFS3:F8EJ+9O&=KU6R[#I=KUM^>IUE
MFT!.Y.1D92-2`37+%\L'KD$7JH`Y_<:ISF)PTY#<8JU98FG3VY]?/*;%V>=:
M/'T1"NG+Y@[*\?M&`@\7;E*S$HE3_-U,&>+T([01\PR]X-@<""/F&6OSEOXH
M-@\CO&-POX&0NV:;6[;Q=_Z30GK[*0DV[KMI#CMJ\]`F_M$8T.629_J)T?Y#
M7WA'VDP[5/7UR0<I\N&'9W=*?*G@K@N-<E-J%_U?7C\ZX'>)D*TM;O#3@_:N
M,7*'R(;]GKS7[1$<T]P4/957K\1'2+.2I3"H5^PP[B-GG3PPM9!V\6FRG(9N
M`$*5,>OJ/H_:)[6^H`?<JI$'#Z4`^X'XLU'-#K3XA.4/%G=^T-Y^(/EO6.,T
M%O&;-:-K\3MUT4]^XXOK@\<`>1MU$%@A)2FNUSIAW$:,XU14O_EDGJ$:5!BW
M=7ZO]WSH6[*4P$0*Q.)CEN!R!0]?`]2*DXX]Q*]9QXJ^?W,?9FO;1Y2^=]?M
M>F=47R'V15N+7#FIS.I*#8+=7GH2$')W'8C\L5?GC5@L0J14CE=OVZ!E!82$
M>X44<'C'\0#-AT>E?MH7`IU#D+D8R>W%@W4N>E<*,U&ZGX*W7E7X<\X.8%8T
M-$\*.:D_PVEM?;)>639$I!3MYKI[O7';)@UCTG"]"<M7EB"L+-W"I(&1.2'E
M3._\Y.044C!4/I]/I\"Q%$3$/F#TIX_!OI5;8LA4JN7*CB5QZYK:BE=&\F=:
M0FT-<R;Q*71BY4SMI(0%C:L9&-CK75)Z,<,IJL6F,92[I)N_9+HN").%4A,*
M2JA#E5&4H'-$L5RCWWQ/^4_PX6ZP;L\/^Y[%R-XYO)5:P7CAQL=-O8)YQ'D*
M47#52E^[%0&SU#-"'2/)ULU=N)D_9;H(.NBBHG,8]L1TZ,[G#Q+L'I$`&KW!
M(70+<F!JQP'<"[T[\(]C46$<9>;'!#F;97=6I$NW\3'.Q28>,+KQQVRR7/PV
MV_?2R;@LXSC8MZ2II:GV!.3ZJ@+#'_I::/)O#_+8VA9(#9E_&N:[[Q>^VV73
M+2&3RLS\UN5?,PJ!(Y2#*!C(D.YCCAO+.!\=Y?8`W.R]]O\`#U%MHW8]6S5S
MQ#DY+@(%2!$N5<NT2=[TU;HS6G)S7C[1E_F7A(RK/GTD6Q:?VE(`A[ARZ?W`
M@QC(*UN5!(H8D+(H0EM30("SB'02.F<_1_%?<W8>1B&FOD:3=),/3F?+*1Z6
M[E`>X2$)'`1*Y8YA[2<CXN):S2Q.NV<!S<MQ.>V.OJVP\HM_;CF@P<RB?*,G
M>/&<<T<OY!VV8L62"KIX]>+I-6C1L@05%G#ERN8B*""*91,8YC`4I0ZB/3-B
MW+ENS;E=O2C"U$$DD@``8DDT`'4E:NLV;VHNQL:>,IWYR`C&(,I2)H``')).
M`%2L;I##:._:U*7;3"=+U]H:%CU96T\T.0;I6I<<Z]`D;*+JV.B(.I.MS6]&
MC4GMJ`\CGL/454S"4;&FL04<TURKW@V[;I2T/'8#5:P4-TOZ,?X6\UPBO]F.
M!$I!;VX?['[IN!CK>52.DT>/HQ/^/+!LQ(,+0([<UP-EE;@XDM?EF\EVH-<[
M=0TQXAM*WGR:<_95-Y#I\R-IU-S9:I0DI(193J6C-=1K&`@J74XU0B17$DU;
M5^%.B0B\G(390.X-SSO&^[IONM.KW>]._J*LY:,`^$8LT8@EB(`!R2'((73>
MR<;V?CFC&CVK36]-I`09"(\\V=I2F7G=D'?-.4B!++$BD1=/C-^W>VWR8V0Q
MY8^;CD%:^1VUGJQ91EQXK=O>A0:NBI\99"O6FVPQHULC$->T2J5ZFHQ,2BNB
M4X2+Y(ZA#^/C6;$D#HPZ],.HZ8Q$BY-/8SQB"(!BS=M,>H=R[$O4`4`H.K>D
MTFH:VJ%8U_K^L05+HU+@HRL5&HUB,:0M>K=>A6B3")A86)8)(,HZ-CF2!$DD
MDB%(0A0``R23(N<5:QJ<5D^0B81,(F$56I7AIH&?Y;U?F_/5:3FN1%&UB_U#
M1[1)6FQ.(2G4N5<RCF40KM-&1+5H^7DOOKY)>0!J+Q5!XJD902"4I18]/I7Z
MZL^+4P50E(1,03E/ZOG@,5:7"I3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBU6>0[PX<(?)-$.GNZ->!5-
MPI1PLJ_R!UF#&L[4B_92,1@VFW_PW,7?8)F)NA6,VV>D03.H#4[50XJ@['Z%
M_I\SWAR0QJJXSE!S%G(:M1VBG<:CO7-EL.J^7GPD5"<UINZAU_RT>*`S)O$S
MD+<(1>T?H:C(=.K*492K:Y7#3#>+39IBD#Y*ST9B`(@W4;NU?[NJ,Y0.<DD]
MU"'C4X8."X/E:3/$`JHB%PY@<LW<]7;S.'-.HJ0S`O\`LG"['Y3?#13ZA4]E
MZ2UORPYC;7M3I$NJ/'WNI],2>I=&WTKEJZ8JV9U)0TU_B>T+-`C]C;/)38YF
M*I`)'HQ0]HH>OJ^0[UKM%#;=9JK]W06RT;<IR(?H""3@X`S`Y"1$97(7BZ7B
M^R:'<;VZZ31Z:UN=V33NB$1-R""Q`)CG$O.8`&;@SS,6L53?&%Y8O--.U_;/
ME9V[.<3.*R;AO-4?B%K)H%9GQBQ5]Z/0'7CM:5BZ0Y;-@`J,I<3SEH;AU2^$
MBD8HYXY)E_"Y^+8%^UZ]HH*5?VGM0I`/3&N+"H%&KA4@,\:R)'4UQ&X.\6."
MVNTM9\7M/5?6,$HFU^^RK!N=_<KF^:(E1)+7>Z29W=EM,B/01*+IR=)N!A(@
M1)("D".X8?3]*MDDES4_3])/Q5L,*$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+Q
M.0JA3$.4IR'*)#D.`&*<I@$#%,40$#%,`]!`?00PBI?JOQT<%]'[OMG)#4O%
MG3E!W9=#@K,7RO5)FU?-%SHJ(OG54C3"I`T-Y-E6.:36@VL<K**',H\,N<PF
M%US=6;[?TU[>JJ,I$")P!)^>-<:JZ6%2F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
?A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
